Nigerian activists move to stop supply of sub-standard HIV/AIDS drugs
Treatment Action Movement (TAM), a coalition of HIV treatment activists in Nigeria, in collaboration with the AIDS Healthcare Foundation (AHF-Nigeria) has instituted a campaign to eliminate the supply of sub-standard antiretrovirals (ARVs) at treatment centers in Nigeria, reports the AllAfrica news service.
The group, while appreciating actions by the federal government to increase access to HIV treatment, stated that there seemed to be clear failure to protect citizens living with HIV/AIDS.
TAM alleged that local drugmaker Tyonex Nigeria, for example, supplies the AZT/3TC/NVP and the TDF/3TC combinations of ARVs with funding from the Millennium Development Goals (MDGs) funds through the Federal Ministry of Health, noting however that distributing a product meant to save and prolong lives could easily be bogged by an integrity deficit in basic physical requirements.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze